Anton Kraxner

Type I IFN controls chikungunya virus via its action on nonhematopoietic cells

Clémentine Schilte, Thérèse Couderc, Fabrice Chrétien et al. · The Journal of Experimental Medicine · 2010 · 310 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies

Sebastian Dziadek, Anton Kraxner, Wei‐Yi Cheng et al. · Frontiers in Immunology · 2024 · 33 citations · Full text

Medicine, Cancer Biology, Oncology +17

Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.

Antoîne Italiano, Loïc Verlingue, Hans Prenen et al. · Journal of Clinical Oncology · 2021 · 23 citations

Medicine, Oncology, Pharmacology +17

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

Loïc Verlingue, Antoîne Italiano, Hans Prenen et al. · EBioMedicine · 2024 · 16 citations · Full text

Medicine, Oncology, Pharmacology +17

Investigating the complex interplay between fibroblast activation protein α-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy

Anton Kraxner, Franziska Braun, Wei‐Yi Cheng et al. · Frontiers in Immunology · 2024 · 15 citations · Full text

Medicine, Cancer Biology, Oncology +17